Department of Psychiatry
The Yale Department of Psychiatry is a world leader in patient care, research, and education. Our department prides itself on its diverse and talented faculty, including a cadre of compassionate clinicians, inter-disciplinary teams of talented investigators, and numerous committed and dedicated teachers, as well as a network of able alumni that remain vital to our missions.
As a department, we not only provide the highest quality of patient care, but also lead the nation in discoveries that are transforming our understanding and treatment of mental illness and addiction.
The department’s Psychology Section, with more than 200 full-time and voluntary faculty, is one of the largest and most accomplished groups of psychologists in an academic medical center.
Latest News
- September 22, 2023Source: Psychological Medicine
In Study of Veterans, Positive Personality Traits Moderate Persistent High Alcohol Consumption
- September 21, 2023Source: PsyPost
A Single Dose of Psilocybin Boosts Neuroplasticity and Reduces Depression Symptoms
- September 20, 2023Source: The Connecticut Post
White: Delayed School Start Times Would Benefit Children
- September 20, 2023
Huckins to Receive 2023 International Society of Psychiatric Genetics Theodore Reich Early Career Award
- September 19, 2023
Investigators Launch Study Aimed at Accelerating Understanding of Bipolar Disorder
- September 18, 2023
Teenage Brain Development Study Forecasts Drinking Behavior by Sex
- September 18, 2023Source: Yale Medicine
What to Know About Zurzuvae, the New Pill to Treat Postpartum Depression
- September 15, 2023
Kaufman to be Appointed Director of The Consultation Center
Pioneering Interventional Psychiatric Services: Yale School of Medicine and Yale New Haven Health
00:02:46
Ketamine Clinical Trial
Parkinson disease not only affects a person's mobility, but also many other symptoms in a person with Parkinson disease life. Depression is a very common symptom caused by Parkinson disease, and adequate treatment is imperative for patients to feel their best. Through collaborations between Drs. Sophie E. Holmes and Gerard Sanacora of Psychiatry and the Movement Disorders group, researchers are conducting the first clinical trial of ketamine as an antidepressant in PD. Due to how it works in the brain – its ability to help form new synapses – they have strong reason to believe it will effectively treat depression, and possibly other symptoms, in PD. Using brain imaging before and after treatment will help to determine how it works in the brains of people with Parkinson’s for the first time. The trial is taking place at the Yale New Haven Psychiatric Hospital. In this video, hear more about the trial from Drs. Holmes and Sanacora and from Brenda, who talks about her experience participating in this groundbreaking research.
Department of Psychiatry Upcoming Events
Yale Only Sidhant ChopraZoom Meeting ID: 964 0112 1764 Password: 593920
Yale Only Susan Abramson
Everyone Samuel Ball, PhD - Jonathan N Grauer, MD
Department of Psychiatry Diversity, Equity and Inclusion Upcoming Events
Yale Only Sidhant ChopraZoom Meeting ID: 964 0112 1764 Password: 593920
Yale Only Susan Abramson
Everyone Samuel Ball, PhD - Jonathan N Grauer, MD